Drug Patent Expirations in September 2010
*Drugs may be covered by multiple patents
|Tradename||Applicant||Generic Name||Patent Number|| Patent Expiration|
|MUSE||Vivus||alprostadil||5,242,391||Sep 7, 2010|
|ADVAIR DISKUS 100/50||Glaxosmithkline||fluticasone propionate; salmeterol xinafoate||RE40045||Sep 7, 2010|
|ADVAIR DISKUS 500/50||Glaxosmithkline||fluticasone propionate; salmeterol xinafoate||RE40045||Sep 7, 2010|
|ZINECARD||Pharmacia And Upjohn||dexrazoxane hydrochloride||5,242,901||Sep 7, 2010|
|ADVAIR HFA||Glaxosmithkline||fluticasone propionate; salmeterol xinafoate||RE40045||Sep 7, 2010|
|ADVAIR DISKUS 250/50||Glaxosmithkline||fluticasone propionate; salmeterol xinafoate||RE40045||Sep 7, 2010|
|DENAVIR||Novartis||penciclovir sodium||6,573,378||Sep 24, 2010|
|DENAVIR||Novartis||penciclovir sodium||5,075,445||Sep 24, 2010|
|NAROPIN||App Pharms||ropivacaine hydrochloride monohydrate||4,870,086||Sep 24, 2010|
|ACCOLATE||Astrazeneca||zafirlukast||4,859,692||Sep 26, 2010|
|ACCOLATE||Astrazeneca||zafirlukast||5,583,152||Sep 26, 2010|
|AGGRASTAT||Medicure||tirofiban hydrochloride||5,658,929||Sep 27, 2010|
|AGGRASTAT||Medicure||tirofiban hydrochloride||5,880,136||Sep 27, 2010|
|FERIDEX I.V.||Amag Pharms Inc||ferumoxides||5,248,492||Sep 28, 2010|
|IMODIUM MULTI-SYMPTOM RELIEF||Mcneil||loperamide hydrochloride; simethicone||5,612,054||Sep 28, 2010|
This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin. Courtesy of DrugPatentWatch.com
I’ve posted a new Orphan Drug Report at thinkPharm.com.
This new report complements the Drug Patent Inventor Report, and profiles pharmaceutical drugs with FDA Orphan Drug Exclusivity.
The Orphan Drug Report includes:
- The tradename, applicant, ingredient, and Orphan exclusivity expiration dates for each Orphan Drug
- Details on each NDA and product number, including Dosage, Strength, Approval Date, Therapeutic Equivalence (TE) code, Reference Listed Drug (RLD) indicator
- All FDA-listed patents covering each Orphan Drug
- More than 100 pages
- More than 80 drugs profiled
A preview of the report is also available.
Do you need any other pharmaceutical drug and patent reports? Let me know.
HealthBank empowering patients with full ownership and control of their stored tumor tissue integral for tailored treatment courses; Six-year brain tumor survivor Bob Gibbs exemplifies the importance of banking tumor tissue for personalized cancer vaccines, which saved his own life
Here’s something to wrap your brain around: tumors saves lives! Few cancer patients realize that tumor tissue is a precious information source that can play a critical role in fighting cancer if – and only if – it is saved at the time of surgery, and properly stored for human use rather than just lab testing.
This because correctly banked tumor tissue can be used for the creation of personalized immune therapies tailored for each patient’s unique tumor profile or “fingerprint,” like the DCVax personalized cancer vaccine from Northwest Biotheraputics (OTCBB:NWBO) that saved the life of Bob Gibbs – now a 6 year survivor of a lethal Grade 3 brain tumor.
“Unfortunately, most cancer patients don’t realize tumor banking services are available, the magnitude of this choice, and critical differences between the types of bio banks in existence,” said Linda Powers, chairman of HealthBank – the only bio bank in the U.S. FDA certified as an eligible (“cGMP”) facility for the production and storage of cells for human use..
With Bob’s notable 6 years of survival from a disease that’s effectively an immediate death sentence, he exemplifies the importance of tumor banking for the hundreds of thousands of terminally-ill cancer patients who now have hope for a longer and brighter future…but unfortunately don’t even know it. “Such tumor banking services for patients have been available in Japan and Germany for years, but is a new opportunity for patients in the U.S. with HealthBank’s FDA certification,” Gibbs notes.
To help expand patient knowledge about, and access to, tumor banking and related medical treatments, Bob has established Miles for Hope (www.MilesforHope.com), a non-profit organization dedicated to raising awareness about brain and other cancer tissue banking and funds to support the cause. Bob’s heroic crusade to educate patients about tumor tissue banking and emerging immunotherapies – even as he battles his own medical issues – personifies selflessness and offers a highly compelling human interest story in this regard.
More information about HealthBank and its services may be accessed online at www.HealthBank.com. View a recent and related press release by Miles for Hope here: http://tinyurl.com/tumorbanking and compelling 5-minute docu-footage of Bob and his physician discussing tumor banking and the DCVax treatment here: http://www.youtube.com/watch?v=n1tCQjoCrOM. Learn more about the DCVax custom cancer vaccine here: www.kerncomm.com/CustomVaccine.doc.
Coming soon, a book by Michael L. Salgaller, PhD. In this new book — Biotechnology Entrepreneurship: From Science to Solutions — Michael combines the voices of a diverse set of industry insiders with extensive experience in biotechnology commercialization to prepares nascent founders, managers, investors, and other biotechnology company stakeholders to position themselves and their companies for commercial success.
Topics covered include:
- Why Start a Biotechnology Company?
- Company Formation and Organization
- Building Your Team
- Intellectual Property Protection Strategy
- Financing Your Company
- Partnering With Industry
- Licensing and Technology Transfer
- Regulatory Affairs
- Roadmap to Reimbursement and Access
- Working Toward a Successful Exit
Full details on the book are available on Logos Press’ website, and the book is available for pre-order at Barnes and Noble and Amazon.com.
Media outlets interested in a review copy can contact firstname.lastname@example.org.
Synthetic biology has been hailed as a revolution in biotechnology, enabling bold new possibilities in areas such as energy production, medicines, and other applications.
But, is it really revolutionary, or just a new tool? With our current knowledge of the structure and function of proteins, the ability for de novo engineering is relatively limited. The near-term use of synthetic biology appears to be as a more-extreme version of gene splicing rather than the design of entirely new organisms, enyzmes, and biochemical pathways.
The good news is that synthetic biology is already paying dividends. For an overview of cases of successful implementation, see BIO’s report: Synthetic Biology and Everyday Products.
Compound registration, structure search and computed properties rolled out.
Budapest, Hungary and Cambridge, Massachusetts, 19 August 2010 – ChemAxon, a leading provider of chemistry software for life sciences, announced today that they have entered into an agreement with the Broad Institute of Harvard and MIT, which will license ChemAxon’s platform, discovery toolkits and desktop applications for institute-wide use. Broad will support their legacy small molecule registration system and other functionality across their Chemical Biology Platform with ChemAxon’s technology.
In addition to ChemAxon’s discovery and desktop tools, the Broad Institute has already updated their core technology for archiving small molecules by deploying the JChem platform toolkit within their existing system.
“This adoption is a part of our strategy to provide our scientists in the Chemical Biology Platform with the most modern and capable tools to accelerate our research,” said Michael Foley, Director of the Broad’s Chemical Biology Platform. “The extensive capabilities of the ChemAxon software support our ongoing efforts to build and apply state of the art facilities to support our work.”
The evaluation and deployment is to be presented during ChemAxon’s User Group Meeting being held in Boston’s Omni Parker House, September 14-15, the complete program is here: http://www.chemaxon.com/events/2010-us-ugm/
ChemAxon is a leader in providing cheminformatics software development platforms and applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions and programming interfaces to power modern cheminformatics and chemical communication. For more information please visit www.chemaxon.com.
Headwaters MB announced that Don Warriner and Brad Rosborough have joined the firm as Managing Directors within the Life Sciences practice.
Don Warriner joined Headwaters from Venture West Partners where he was focused on capital formation, sell-side and buy-side opportunities in software / technology companies. Don previously was an executive at IBM and the CEO at Data National Corp.
Brad Rosborough joined Headwaters from Three-Sixty Advisory Group, LLC where he was focused on strategy work with emerging healthcare companies. Brad has previously worked as an executive at several large organizations including Anthem Health, FHP International Corp. and Bio Cybernetics International.
“Don and Brad round out our Life Sciences practice with terrific transaction and operations experience with both emerging and large established companies in their space,” said Philip W. Seefried, the Co-Founder & CEO of Headwaters. “They complement our existing biotech practice and bring an expert-level focus to our clients.”